Last reviewed · How we verify
mRNA-1010
mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells.
mRNA-1010 is a therapeutic cancer vaccine that encodes personalized tumor-associated neoantigens to stimulate the patient's immune system to recognize and attack cancer cells. Used for Melanoma (adjuvant setting, in combination with Merck's Keytruda), Non-small cell lung cancer (adjuvant setting, in combination with checkpoint inhibitor).
At a glance
| Generic name | mRNA-1010 |
|---|---|
| Also known as | Seasonal influenza vaccine |
| Sponsor | ModernaTX, Inc. |
| Drug class | Personalized neoantigen vaccine |
| Target | Patient-specific tumor neoantigens |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This mRNA vaccine is designed to be personalized for each patient based on their tumor's unique mutation profile. It encodes multiple neoantigens derived from the patient's own cancer, which are presented to the immune system to generate CD8+ and CD4+ T-cell responses against tumor-specific mutations. The approach aims to enhance anti-tumor immunity and reduce recurrence risk.
Approved indications
- Melanoma (adjuvant setting, in combination with Merck's Keytruda)
- Non-small cell lung cancer (adjuvant setting, in combination with checkpoint inhibitor)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
- Myalgia
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (PHASE3)
- A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults (PHASE1, PHASE2)
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older (PHASE3)
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (PHASE2)
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |